Past, Present and Future: SGLT2 inhibitors for CV Outcomes - Round Table

Past, Present and Future: SGLT2 Inhibitors for Cardiovascular Outcomes - How Did We Get Here?

Educational objectives

  • Understand the history of SGLT2 inhibitors and the published data from SGLT-2 inhibitor cardiovascular outcome trials (CVOT).
  • Link these outcomes data to the latest guideline updates in diabetes.
  • Understand the importance of the ongoing CREDENCE, EMPA and DAPA clinical trials.
  • Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.
  • Apply this clinical understanding to the management of heart failure patients in the real world.
  • Identify important future developments to be aware of to allow continual optimisation of heart failure management and the potential for future guideline updates in heart failure.
  • Assess the interrelationships linking diabetes, HF and CVD.

 


Programme Outline
  • How did we get here? Andrew JS CoatsFaiez ZannadStefan AnkerJohn McMurray
  • Where are we now? Andrew JS CoatsFaiez ZannadStefan AnkerJohn McMurray
  • What is the future?Andrew JS CoatsFaiez ZannadStefan AnkerJohn McMurray
This video series was funded by an unrestricted educational grant from Boehringer Ingelheim.

Past, Present and Future: SGLT2 Inhibitors for Cardiovascular Outcomes - Where are we now?